Thomas R. Talbot, MD, MPH; Dale W. Bratzler, DO, MPH; Ruth M. Carrico, PhD, RN; Daniel J. Diekema, MD; Mary K. Hayden, MD; Susan S. Huang, MD, MPH; Deborah S. Yokoe, MD, MPH; Neil O. Fishman, MD; for the Healthcare Infection Control Practices Advisory Committee
Disclaimer: The findings in this report are those of the authors and do necessarily represent the official position of the Centers for Disease Control and Prevention or the Department of Health and Human Services.
Acknowledgment: The authors thank the other advisory and liaison members of HICPAC for their thoughtful discussion and insight on this topic and white paper.
Potential Conflicts of Interest: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M13-1120.
Requests for Single Reprints: Thomas R. Talbot, MD, MPH, Vanderbilt University Medical Center, A2200 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232; e-mail, firstname.lastname@example.org.
Current Author Addresses: Dr. Talbot: Vanderbilt University Medical Center, A2200 Medical Center North, 1161 21st Avenue South, Nashville, TN 37232.
Dr. Bratzler: OU Physicians Executive Office, Oklahoma University Health Sciences Center, 1200 North Children's Avenue, Suite 3200, Oklahoma City, OK 73104.
Dr. Carrico: Division of Infectious Diseases, University of Louisville School of Medicine, 501 East Broadway, Suite 120, Louisville, KY 40202.
Dr. Diekema: University of Iowa Carver College of Medicine, 200 Hawkins Drive, Iowa City, IA 52242.
Dr. Hayden: Rush University Medical Center, 1653 West Congress Parkway, Chicago, IL 60612.
Dr. Huang: Division of Infectious Diseases, University of California, Irvine, 101 The City Drive, City Tower, Suite 400, ZC 4081, Orange, CA 92868.
Dr. Yokoe: Brigham and Women's Hospital, Channing Laboratory, 181 Longwood Avenue, Boston, MA 02115.
Dr. Fishman: University of Pennsylvania, One Convention Avenue, Penn Tower, Suite 101, Philadelphia, PA 19104.
Author Contributions: Conception and design: T.R. Talbot, D.W. Bratzler, R.M. Carrico, D.J. Diekema, N.O. Fishman.
Analysis and interpretation of the data: T.R. Talbot, M.K. Hayden, N.O. Fishman.
Drafting of the article: T.R. Talbot, D.S. Yokoe, N.O. Fishman.
Critical revision of the article for important intellectual content: T.R. Talbot, D.W. Bratzler, R.M. Carrico, D.J. Diekema, M.K. Hayden, S.S. Huang, D.S. Yokoe, N.O. Fishman.
Final approval of the article: T.R. Talbot, D.W. Bratzler, R.M. Carrico, D.J. Diekema, M.K. Hayden, S.S. Huang, D.S. Yokoe, N.O. Fishman.
Administrative, technical, or logistic support: T.R. Talbot.
Collection and assembly of data: T.R. Talbot, R.M. Carrico.
Health care–associated infection (HAI) rates are used as measures of a health care facility's quality of patient care. Recently, these outcomes have been used to publicly rank quality efforts and determine facility reimbursement. The value of comparing HAI rates among health care facilities is limited by many factors inherent to HAI surveillance, and incentives that reward low HAI rates can lead to unintended consequences that can compromise medical care surveillance efforts, such as the use of clinical adjudication panels to veto events that meet HAI surveillance definitions.
The Healthcare Infection Control Practices Advisory Committee, a federal advisory committee that provides advice and guidance to the Centers for Disease Control and Prevention (CDC) and the Secretary of the Department of Health and Human Services about strategies for surveillance, prevention, and control of HAIs, assessed the challenges associated with using HAI surveillance data for external quality reporting, including the unintended consequences of clinician veto and clinical adjudication panels. Discussions with stakeholder liaisons and committee members were then used to formulate recommended standards for the use of HAI surveillance data for external facility assessment to ensure valid comparisons and to provide as level a playing field as possible.
The final recommendations advocate for consistent, objective, and independent application of CDC HAI definitions with concomitant validation of HAIs and surveillance processes. The use of clinician veto and adjudication is discouraged.
Table 1. Timeline of Key Events in CDC HAI Surveillance
Table 2. Examples of Clinician Veto of an NHSN-Defined HAI Surveillance Event
The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.
Talbot TR, Bratzler DW, Carrico RM, Diekema DJ, Hayden MK, Huang SS, et al. Public Reporting of Health Care–Associated Surveillance Data: Recommendations From the Healthcare Infection Control Practices Advisory Committee. Ann Intern Med. ;159:631–635. doi: 10.7326/0003-4819-159-9-201311050-00011
Download citation file:
Published: Ann Intern Med. 2013;159(9):631-635.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use